Quantcast
Last updated on April 16, 2014 at 7:44 EDT

Latest Shield Therapeutics Stories

2013-12-16 04:21:44

LONDON, December 16, 2013 /PRNewswire/ -- Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia (IDA) in pre-dialysis patients with chronic...

2013-11-12 04:22:34

LONDON, November 12, 2013 /PRNewswire/ -- Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia (IDA) in pre-dialysis patients with...

2013-10-23 04:23:18

LONDON, October 23, 2013 /PRNewswire/ -- Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that Richard Jones, Chief Financial Officer, and Angela Hildreth, Group Financial Controller, will attend BIO-Europe(R) [http://www.ebdgroup.com/bioeurope/index.php ]2013 which takes place on Monday 4th to Wednesday 6th November in Vienna, Austria. If you would like to...

2013-06-24 04:20:55

LONDON, June 24, 2013 /PRNewswire/ -- Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally. Patients with inflammatory bowel disease and anaemia have been recruited and randomised when oral ferrous products have been ineffective due to...

2011-10-12 01:00:00

LONDON, October 12, 2011 /PRNewswire/ -- - Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease - Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase...

2011-06-01 02:00:00

LONDON, June 1, 2011 /PRNewswire/ -- - New Investment to Further Fund the Phase III Clinical Programme of ST10-021 in Iron Deficiency Anaemia Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has successfully raised EUR8.2m (CHF10m/US$12m) from Inventages Venture Capital (Inventages) in its first institutional (Series A) financing round....